BMS files Opdivo/Yervoy combo for lung cancer

22nd June 2018 Uncategorised 0

US regulators have accepted Bristol-Myers Squibb’s application to market its immunotherapy Opdivo plus Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in certain patients.

More: BMS files Opdivo/Yervoy combo for lung cancer
Source: News